A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting

Clinical trial NCT07073079 · RECRUITING

Trial details

NCT number: NCT07073079
Sponsor: AbbVie
Status: RECRUITING
Study type: OBSERVATIONAL

Crohn's Disease

Start date: 2025-07-14
Primary completion: 2027-12-01
Enrollment: 250

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.